Key result
TNF-α antagonists show no benefit in chronic HF due to double-edged effects on failing myocardium.
Why the study?
Do TNF-α antagonists provide clinical benefit in patients with chronic heart failure?
Population
Patients with chronic heart failure (CHF)
Design
Review
Authors
Loading...
TNF-α antagonists lack benefit in chronic HF; leaves open whether selective inflammatory pathway modulation warrants targeted trials.
Do TNF-α antagonists provide clinical benefit in patients with chronic heart failure?
This review highlights the complex, double-edged effects of TNF-α and related proinflammatory pathways in chronic heart failure, explaining why TNF-α antagonists have failed to show clinical benefit.
Hori et al. (2013) conducted a review in Chronic Heart Failure (CHF). TNF-α antagonists was evaluated. Clinical trials using TNF-α antagonists did not show a benefit of TNF-α inhibition in patients with chronic heart failure, reflecting the double-edged effects of TNF-α on failing myocardium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: